Introduction
Aortic stenosis is nowadays the most common native valve disease occurring primarily among elderly patients [1] . It has been shown that moderate-to-severe aortic stenosis is associated with disturbances in blood coagulation, both bleeding, which is mostly caused by acquired von Willebrand disease [2] , and less frequently, thrombosis [3, 4] . Data about a hypercoagulable state in aortic stenosis are sparse. It has been demonstrated that in patients with obstructed left ventricular outflow tract due to hypertrophic cardiomyopathy and aortic stenosis, platelet activation and thrombin generation markers are higher and are positively correlated with transvalvular pressure gradient [5, 6] .
Tissue factor (TF) is a key initiator of blood coagulation in vivo. TF is continuously expressed on subendothelial cells and upon vascular injury forms a complex with circulating factor (F)VIIa initiating blood coagulation [7] . There have been reports that strongly indicate the importance of TF in the pathogenesis of atherosclerosis and its relation with cardiovascular risk factors. Increased TF levels in circulating blood have been observed in patients with diabetes and hypertension [8] . In early stages of atherogenesis, increased expression of TF is detectable on monocytes, in foam and smooth muscle and endothelial cells [8] .
FXIa is a serine protease that activates FIX to FIXa leading to the intrinsic FXase (FIXa/FVIIIa/Ca þþ /membrane) formation and to ultimate amplification of thrombin generation. Under physiologic conditions, a key activator of FXI is thrombin [9] . A similar mechanism of FXI activation was suggested for patients suffering from coronary artery disease (CAD) and chronic obstructive pulmonary disease [10] [11] [12] .
In 2008, we reported that in plasma samples from patients with acute coronary syndromes (ACSs) and less commonly in those with stable CAD, FXIa and TF can be detected, whereas in plasma of healthy individuals, active TF and FXIa are not observed [11] . There are many similarities between the pathogenesis of aortic sclerosis/ stenosis and atherosclerosis [13, 14] . It has been established that in aortic stenosis patients, there are atherosclerosis-like lesions in the aortic leaflets, including macrophage accumulation [14] . Additionally, risk factors for aortic stenosis and atherosclerosis are similar [14] [15] [16] [17] [18] [19] [20] .
Patients and methods
Patients Fifty-four consecutive adult patients with calcific aortic stenosis were enrolled. The Jagiellonian University Ethical Committee approved the study, and patients provided written, informed consent. The inclusion criterion was a mean transvalvular pressure gradient higher than 20 mmHg measured in transthoracic echocardiography. In patients with atrial fibrillation or taking oral anticoagulants, thienopyridines and heparins were excluded. Other exclusion criteria were impaired left ventricular systolic function (left ventricular ejection fraction < 50%), more than mild concomitant valvular disease, rheumatic aortic stenosis, history of endocarditis, aortic aneurysm, acute cardiovascular event within the previous 6 months, acute illness (symptoms and/or C-reactive protein >10 mg/l), more than stage 2 of chronic kidney disease, hepatic insufficiency, severe pulmonary disease, and cancer. Clinical characteristics of the study population are presented in Table 1 .
Echocardiography
Transthoracic echocardiographic examinations were performed with the use of the Aplio SSA-770A echocardiograph (Toshiba, Tokyo, Japan). Images were stored digitally and analyzed offline by an experienced echocardiographer. Measurements were made in conventional parasternal, four-chamber and five-chamber apical views using M-mode two-dimensional Color Doppler, pulsedwave Doppler, and continuous-wave Doppler according to the European Society of Echocardiography guidelines. The transvalvular gradient and peak velocity were measured by Doppler echocardiography with the use of the modified Bernoulli equation. Aortic valve opening area (AVA) was calculated using the standard continuity equation [21] . Left ventricular volume and ejection fraction were measured by the modified Simpson method [22] . Left ventricular mass, left atrial volume, and AVA were indexed to body surface area. Aortic stenosis was considered as moderate if the mean transvalvular pressure gradient was 20-40 mmHg and severe if the mean transvalvular pressure gradient was higher than 40 mmHg [23] .
Laboratory methods Blood samples were obtained from patients with aortic stenosis between 0800 and 1000 h on the day of echocardiographic examination after an overnight fasting, with minimal stasis applied during blood draw. Blood cell counts and biochemical analysis, including lipid profile, creatinine, and glucose were assessed by standard automated laboratory methods. Venous blood samples for clotting assays were taken into 0.13 mol/l trisodium citrate tubes (Becton Dickinson, Franklin Lakes, New Jersey, USA) and centrifuged for 20 min within 10 min of collection at 24 8C and 2500g. Platelet-poor plasma was immediately frozen and stored at À80 8C. Fibrinogen and C-reactive protein were assayed by immunonephelometry (Dade Behring, Marburg, Germany). To assess thrombin generation in circulating blood, prothrombin fragment 1.2 (F1.2) in citrate plasma was measured using an immunoenzymatic assay (Dade Behring). All intra-assay and interassay coefficients of variation were less than 7%.
Plasma clotting assays
Plasma clotting assays were performed as described previously [11] . Briefly, plasma was thawed at 37 8C in the presence of corn trypsin inhibitor (prepared as previously described [24] ; blocks the contact pathway of blood coagulation by inhibiting FXI activation by FXIIa) and either buffer or inhibitory monoclonal anti-FXI (aFXI-2) or anti-TF (aTF-5) antibody (both produced in house) at a final 0.1 mg/ml concentration. CaCl 2 at a final 15 mmol/l concentration was added and clotting was initiated by the Data are given as mean AE SD or n (%). CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.
addition of 2 mmol/l phospholipid vesicles (prepared as previously described [24] ) composed of 25% dioleoyl-snglycero-3-phospho-L-serine and 75% 1,2-dioleoyl-snglycero-3-phosphocholine (both from Avanti Polar Lipids Inc., Alabaster, Alabama, USA 
Results

Patient characteristics
A total of 54 patients (37 men and 17 women, aged 43-83 years) were studied. Sixteen had moderate aortic stenosis and 38 had severe aortic stenosis. The groups did not differ significantly with regard to age, sex, BMI, the frequency of CAD, hypertension, diabetes, and smoking habit (Table 1) . Lipid profile, creatinine, and platelet count were comparable between the moderate and severe aortic stenosis groups. The maximal and mean transvalvular pressure gradients ranged from 39 to 147 mmHg and from 20 to 84 mmHg, respectively. All patients had preserved left ventricular function with a mean left ventricular ejection fraction of 62.4%. Six patients in the moderate aortic stenosis group were diagnosed with left ventricular hypertrophy, defined as left ventricular mass index more than 110 g/m 2 for women or more than 134 g/m 2 for men. Sixteen patients (42%) in the severe aortic stenosis group had this condition. The remaining echocardiographic parameters were similar for both groups (Table 2) .
Clotting variables
In severe aortic stenosis patients, F1.2 was elevated compared with that in moderate aortic stenosis (P ¼ 0.006). There was a positive correlation between F1.2 and both maximal (r ¼ 0.71; P < 0.001, Fig. 1a) and mean (r ¼ 0.68; P < 0.001, Fig. 1b) Fig. 1d ).
Active TF was detectable in plasma from 14 patients (25.9%), that is, in one of 16 patients with moderate aortic stenosis (6.25%) and in 13 of 38 patients (34.2%) with severe aortic stenosis ( Table 3 ). In most patients (nine of 14 patients; 64.3%), TF activity was low, below 0.4 pM. Five patients, all from the severe aortic stenosis group, had higher active TF levels up to 3.4 pM.
When the severe aortic stenosis patients were divided in two subgroups based on the presence or absence of TF activity, in the TF(þ) subgroup, the mean F1.2 concentration was significantly higher (375 AE 122 vs. 207 AE 64 pM, P < 0.001; Fig. 2 ). Severe patients with detectable TF had higher maximal (111 AE 20 vs. 97 AE 16 mmHg, P ¼ 0.02) and mean (61 AE 12 vs. 53 AE 8 mmHg, P ¼ 0.02) transvalvular gradient, compared with those without such activity in plasma. Interestingly, the TF(þ) subgroup was younger than the TF(À) subgroup (58 AE 10 vs. 66 AE 11, P ¼ 0.03).
Circulating FXIa was detected in 12 patients with aortic stenosis (21.8%), including 11 patients with severe aortic stenosis (28.9%). Concentrations reached as high as 105 pM. Importantly, all 12 of the patients with FXIa had active TF as well. The patients with FXIa present in their plasma had higher transvalvular gradient that corresponded with the severity of aortic stenosis; however, there was no correlation between the plasma level of FXIa and maximal transvalvular gradient (r ¼ 0.32, Factor XIa and tissue factor in aortic stenosis Luszczak et al. 475 
Discussion
The present study is the first to demonstrate quantifiable active FXIa, not inhibited by plasma serpins, circulating in aortic stenosis patient blood and accompanied by procoagulant TF activity. Previously, circulating FXIa was detected in 96% of patients with acute myocardial infarction (MI) and 76% of patients with a history of previous MI. TF activity was observed in 38% of acute MI patients and only 7% of stable CAD patients with previous MI [11] . In the current study, the activity of circulating TF in the aortic stenosis patients was similar to that observed in acute coronary ischemia, whereas FXIa levels were only slightly lower compared to those observed in stable patients following AMI. The presence of FXIa and TF activity in both advanced aortic stenosis and CAD provides additional evidence for the similarities in the pathogenesis of both common diseases.
The current study corroborates the previous observation showing enhanced thrombin generation reflected by increased plasma F1.2 in aortic stenosis patients [5] .
We have also observed that in aortic stenosis patient population, F1.2 is positively correlated with transvalvular pressure gradient. The lack of significant correlations between AVA and thrombin generation markers (despite their higher levels in patients with TF and XIa) is unexpected. It appears that an increase in thrombin generation observed in aortic stenosis like in hypertrophic cardiomyopathy [6] is a gradient-related phenomenon alone. The association between the levels of the thrombin marker and FXIa suggests that most likely thrombin accounts for FXI activation in severe aortic stenosis [11] . Moreover, higher concentrations of F1.2 in patients with detectable activity of TF in plasma might indicate that TF is associated with enhanced thrombin generation occurring in aortic stenosis.
The significance of circulating active TF in plasma of aortic stenosis patients remains obscure. Marechaux et al. [25] in the experimental study on animals found that lesions on aortic valve leaflets display TF expression. Natorska et al. [26] confirmed the presence of TF in aortic valves, predominately on the aortic side, examined after aortic valve replacement in patients with severe aortic stenosis. The percentage of the area showing TF expression correlated with plasma TF measured using a commercially available immunoenzymatic assay. Very recently, the presence of TF in human stenotic valve leaflets close to calcification regions has also been shown by Breyne et al. [27] . In the present study, we observed that in aortic stenosis patients with high transvalvular pressure gradient, there is an increased probability of procoagulant activity of TF in circulating blood. It remains to be established whether this activity is associated with TF expression within the aortic valves.
The biological effect of increased thrombogenicity in aortic stenosis patients is not clear. Despite enhanced activity of TF and FXIa and elevated platelet activation and thrombin generation markers, clinically evident thromboembolic events are infrequent. The explanation for this apparent discrepancy could be related to the compensation of increased thrombogenicity by impaired platelet function caused by the loss of largest multimers of the von Willebrand factor, which can lead to bleeding tendency observed in some patients with moderate-to-severe aortic stenosis [28] . However, it might be speculated that a subset of aortic stenosis patients positive for circulating TF and/or FXIa are at an increased risk of thrombotic manifestations. A larger study with a long follow-up would be needed to address this issue.
It should be emphasized that in stable aortic stenosis patients, detectable amounts of active FXIa are permanently present in plasma despite the abundance of numerous inhibitors for serine proteases because none of the physiologic inhibitors can effectively inhibit FXIa [29] . As a consequence, 80-90% of FXIa can survive in blood for the 30 min or more required for citrate plasma preparation [11] . The presence of FXIa cannot be attributed to de-novo FXIa generation observed in tubes containing citrate plasma at room temperature over a period of 75 min either in the presence or absence of contact pathway inhibition [11] . These data indicate that plasma FXIa in the aortic stenosis patients does indeed reflect the in-vivo levels of this enzyme.
According to European Society of Cardiology guidelines, aortic valve replacement is recommended in severe
Factor XIa and tissue factor in aortic stenosis Luszczak et al. 477 aortic stenosis either when symptoms occur (spontaneously or in exercise test) or when there is impairment of left ventricular systolic function (ejection fraction < 50%) [30] . Management of asymptomatic aortic stenosis patients with preserved left ventricular function requires weighing the benefits and the risk associated with surgery. There are factors that indicate early surgical treatment, such as excessive left ventricular hypertrophy, fast peak velocity progression, and massive valve calcification [30] . It remains to be established in a larger prospective cohort study whether FXIa and TF activities and their association with thrombin generation could be useful for the prognosis of aortic stenosis and might represent a new indication for earlier surgery.
The study has several limitations. First, the number of patients studied was limited. Second, our analysis was based on the determination of each variable at a single time point. It is likely that with time, TF and FXIa would change (most likely increase) in aortic stenosis patients. Third, the impact of asymptomatic CAD cannot be excluded. However, in the current study, a small subset of aortic stenosis patients who had symptomatic advanced CAD did not differ from patients without it with respect to FXIa and TF activity. Fourth, patients with mild aortic stenosis were not included as our previous observations indicate that such patients had TAT and F1.2 levels within the normal range (data not shown). Finally, our hypothesis-generating study needs to be validated because the clinical significance of our findings is unclear. It might be speculated that TF and/or FXIa increases the risk of thromboembolic events and contributes to the lesion growth within aortic valve leaflets.
In conclusion, FXIa and TF activity associated with thrombin generation was observed in a fraction of patients with aortic stenosis, almost exceptionally in those with a severe manifestation of the disease. This observation suggests that quantitation of these two proteins could have certain potential for the stratification of severe and moderate aortic stenosis patients. However, further prospective studies using a larger patient population are needed to evaluate clinical outcomes relevant to the presence or absence of these factors and related thrombin formation.
